Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Open Forum Infectious Diseases Année : 2018

Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial

Résumé

We evaluated the impact of on-demand oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) for pre-exposure prophylaxis (PrEP) on herpes simplex virus (HSV)-1/2 incidence among men who have sex with men (MSM) enrolled in the ANRS IPERGAY trial. Serum samples were tested at baseline and at the last visit for HSV-1/2 antibodies. Overall HSV-1 incidence was 11.7 per 100 person-years; 16.2 and 7.8 per 100 person-years in the TDF/FTC and placebo arm, respectively (P = .19). Overall HSV-2 incidence was 7.6 per 100 person-years; 8.1 and 7.0 per 100 person-years in the TDF/FTC and placebo arm, respectively (P = .75). On-demand oral PrEP with TDF/FTC failed to reduce HSV-1/2 incidence in this population.
Fichier principal
Vignette du fichier
ofy295.pdf (155.29 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03722664 , version 1 (13-07-2022)

Identifiants

Citer

Marie-Laure Chaix, Isabelle Charreau, Claire Pintado, Constance Delaugerre, Nadia Mahjoub, et al.. Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial. Open Forum Infectious Diseases, 2018, 5 (11), pp.ofy295. ⟨10.1093/ofid/ofy295⟩. ⟨hal-03722664⟩
13 Consultations
101 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More